PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER PATIENTS ACCORDING TO THEIR CLINICAL PREDICTORS

被引：0
|
作者：
Lee, D. H. [1 ]
Kim, H. T. [2 ]
Kim, S. [1 ]
Suh, C. [1 ]
Lee, J. [1 ]
机构：
[1] Asan Med Ctr, Dept Internal Med, Div Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [21] Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer
    Piperdi, Bilal
    Walsh, William V.
    Bradley, Kendra
    Zhou, Zheng
    Bathini, Venu
    Hanrahan-Boshes, Meredith
    Hutchinson, Lloyd
    Perez-Soler, Roman
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : 1032 - 1040
  • [22] PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR
    Murphy, Felicity
    Church, David N.
    Medley, Louise
    Davies, J. M.
    Breen, David
    Clelland, Colin
    Mackintosh, David
    Mugalaasi, Hood
    Butler, Rachel
    Talbot, Denis C.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1250 - S1250
  • [23] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    BMJ OPEN, 2015, 5 (07):
  • [24] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    F Cappuzzo
    S Novello
    F De Marinis
    V Franciosi
    M Maur
    A Ceribelli
    V Lorusso
    F Barbieri
    L Castaldini
    E Crucitta
    L Marini
    S Bartolini
    G V Scagliotti
    L Crinò
    British Journal of Cancer, 2005, 93 : 29 - 34
  • [25] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    Cappuzzo, F
    Novello, S
    De Marinis, F
    Franciosi, V
    Maur, M
    Ceribelli, A
    Lorusso, V
    Barbieri, F
    Castaldini, L
    Crucitta, E
    Marini, L
    Bartolini, S
    Scagliotti, GV
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2005, 93 (01) : 29 - 34
  • [26] First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
    Georgoulias, V
    Androulakis, N
    Dimopoulos, AM
    Kourousis, C
    Kakolyris, S
    Papadakis, E
    Apostolopoulou, F
    Papadimitriou, C
    Vossos, A
    Agelidou, M
    Heras, P
    Tzannes, S
    Vlachonicolis, J
    Mavromanolakis, E
    Hatzidaki, D
    ANNALS OF ONCOLOGY, 1998, 9 (03) : 331 - 334
  • [27] Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    Lorusso, V
    Carpagnano, F
    Frasci, G
    Panza, N
    Di Rienzo, G
    Cisternino, ML
    Napoli, G
    Orlando, S
    Cinieri, S
    Brunetti, C
    Palazzo, S
    De Lena, M
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 405 - 411
  • [28] Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    Lorusso, V
    Crucitta, E
    Panza, N
    Silvestris, N
    Guida, M
    Carpagnano, F
    Mancarella, S
    Sambiasi, D
    De Lena, M
    ANNALS OF ONCOLOGY, 2002, 13 (12) : 1862 - 1867
  • [29] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study (vol 31, pg 3457, 2011)
    Cecere, S. C.
    Cannella, L.
    Rossetti, S.
    Di Napoli, M.
    Pisano, C.
    Fiore, F.
    Striano, S.
    Marra, L.
    Pignata, S.
    Facchini, G.
    ANTICANCER RESEARCH, 2012, 32 (08) : 3592 - 3592
  • [30] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Argiris, A
    Mittal, N
    LUNG CANCER, 2004, 43 (03) : 317 - 322
12345